Jeffrey B Matthews
Overview
Explore the profile of Jeffrey B Matthews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
2206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rao S, Deshpande N, Richardson D, Brickman J, Posner M, Matthews J, et al.
Ann Surg Open
. 2023 Aug;
4(1):e260.
PMID: 37600898
Background: Surgeon productivity is measured in relative value units (RVUs). The feasibility of attaining RVU productivity targets requires surgeons to have enough allocated block time to generate RVUs. However, it...
12.
Pathak K, Marwaha J, Chen H, Krumholz H, Matthews J
medRxiv
. 2023 May;
PMID: 37205325
Open science practices are research tools used to improve research quality and transparency. These practices have been used by researchers in various medical fields, though the usage of these practices...
13.
Spanknebel K, Ellison E, Nagler A, Shabahang M, Matthews J, Stain S, et al.
J Am Coll Surg
. 2022 Dec;
238(5):942-959.
PMID: 36472390
Background: This study assessed the national impact of the coronavirus disease 2019 (COVID-19) pandemic on the education of medical students assigned to surgery clerkship rotations, as reported by surgery clerkship...
14.
Lang J, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):128.
PMID: 36456573
HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with...
15.
Zakrison T, Essig R, Polcari A, McKinley W, Arnold D, Beyene R, et al.
Ann Surg
. 2022 Aug;
277(1):66-72.
PMID: 35997268
Objective: The aim of this review was to review the ethical and multidisciplinary clinical challenges facing trauma surgeons when resuscitating patients presenting with penetrating brain injury (PBI) and multicavitary trauma....
16.
Ellison E, Spanknebel K, Farmer D, Matthews J, Stain S, Shabahang M, et al.
J Am Coll Surg
. 2022 Jul;
235(2):195-209.
PMID: 35839394
Background: A previous survey documented the severe disruption of the coronavirus disease 2019 pandemic on surgical education and trainee well-being during the initial surge and systemic lockdowns. Herein, we report...
17.
Witmer H, Keceli C, Morris-Levenson J, Dhiman A, Kratochvil A, Matthews J, et al.
Ann Surg
. 2022 Jul;
277(5):e1006-e1017.
PMID: 35796435
Objective: To propose a framework for quantification of surgical team familiarity. Background: Operating room (OR) teamwork quality is associated with familiarity among team members and their individual specialization. We describe...
18.
Wolf D, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher R, Lee P, et al.
Cancer Cell
. 2022 May;
40(6):609-623.e6.
PMID: 35623341
Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer subtypes incorporating tumor biology beyond clinical hormone receptor (HR) and...
19.
Clark A, Yau C, Wolf D, Petricoin E, J van t Veer L, Yee D, et al.
Nat Commun
. 2021 Nov;
12(1):6428.
PMID: 34741023
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast...
20.
Yee D, Isaacs C, Wolf D, Yau C, Haluska P, Giridhar K, et al.
NPJ Breast Cancer
. 2021 Oct;
7(1):131.
PMID: 34611148
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab...